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platelet‑primed interactions 
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thrombus formation
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Luca Spiezia2, René van Oerle1, Isabella Provenzale1, Remco Verdoold1, Richard W. Farndale4, 
Kenneth J. Clemetson5, Henri M. H. Spronk1, Paola E. J. van der Meijden1, Rachel Cavill6, 
Marijke J. E. Kuijpers1, Elisabetta Castoldi1, Paolo Simioni2,7* & Johan W. M. Heemskerk1,7*
In haemostasis and thrombosis, platelet, coagulation and anticoagulation pathways act together 
to produce fibrin‑containing thrombi. We developed a microspot‑based technique, in which we 
assessed platelet adhesion, platelet activation, thrombus structure and fibrin clot formation in real 
time using flowing whole blood. Microspots were made from distinct platelet‑adhesive surfaces in 
the absence or presence of tissue factor, thrombomodulin or activated protein C. Kinetics of platelet 
activation, thrombus structure and fibrin formation were assessed by fluorescence microscopy. 
This work revealed: (1) a priming role of platelet adhesion in thrombus contraction and subsequent 
fibrin formation; (2) a surface‑independent role of tissue factor, independent of the shear rate; (3) 
a mechanism of tissue factor‑enhanced activation of the intrinsic coagulation pathway; (4) a local, 
suppressive role of the anticoagulant thrombomodulin/protein C pathway under flow. Multiparameter 
analysis using blood samples from patients with (anti)coagulation disorders indicated characteristic 
defects in thrombus formation, in cases of factor V, XI or XII deficiency; and in contrast, thrombogenic 
effects in patients with factor V‑Leiden. Taken together, this integrative phenotyping approach of 
platelet–fibrin thrombus formation has revealed interaction mechanisms of platelet‑primed key 
haemostatic pathways with alterations in patients with (anti)coagulation defects. It can help as an 
important functional add‑on whole‑blood phenotyping.
In the processes of haemostasis and thrombosis, platelet and coagulation pathways are tightly linked, with plate-
lets both responding to thrombin and fibrin and, conversely, providing a phosphatidylserine-exposing surface 
on which high levels of thrombin and fibrin are  formed1–4. Thrombotic and bleeding disorders are mostly related 
to a dysregulation of one of these pathways, for instance when linked to platelet or coagulation factor mutations, 
or to the (combined) use of antiplatelet or anticoagulant medication.
In the last decade, it has become clear that the accumulation of a platelet- and fibrin-containing plug or 
thrombus is instrumental to the onset of haemostatic as well as thrombotic  events5–7. An important modifying 
factor in thrombus development is provided by the local blood  flow8,9. This implies that, for adequate and com-
prehensive monitoring of the thrombotic process, measurements are to be performed under conditions of flow, 
preferentially recording both platelet and coagulation activation at the same time.
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Recently, we have described a microspot-based whole blood flow test, allowing combined measurements of 
platelet activation processes at multiple different adhesive  surfaces10. This work has revealed the roles of specific 
adhesive receptors in the thrombus-formation process in a shear rate-dependent way, i.e. glycoprotein (GP)
Ib-V–IX (receptor for von Willebrand factor, VWF), GPVI and integrin α2β1 (receptors for collagens and col-
lagen peptides), CLEC2 (receptor for podoplanin and rhodocytin), and integrin α6β1 (laminin receptor). Other 
flow measurements have demonstrated that the formation of a platelet thrombus is supported by the presence 
of tissue factor (TF)—acting via the extrinsic activation of factor (F)VII11,12. On the other hand, collagens and 
polyphosphates can trigger the intrinsic coagulation pathway through direct activation of  FXII13,14. Phosphati-
dylserine exposure promotes the procoagulant role of platelets by markedly enhancing tenase activity (FX activa-
tion by FIXa and FVIIIa) and prothrombinase activity (prothrombin activation by FXa and FVa)9,15. Thrombin 
formation and clotting processes are restricted by natural anticoagulation pathways. The latter act by inhibiting 
activated coagulation factors (via antithrombin and tissue factor pathway inhibitor); and by inactivating FVa 
and FVIIIa through an (endothelial-derived) thrombomodulin and protein C pathway. Protein S is a cofactor 
for activated protein C (APC) in the inactivation of FVa and  FVIIIa16. Currently, there is still a gap of knowledge 
of the relative contributions of the various coagulation and anticoagulation mechanisms in thrombus and fibrin 
formation under flow conditions.
In the present paper, we aimed to identify and characterize principal pathways that regulate the prothrombotic 
interactions between platelet and coagulation activation in flowing whole blood. For this purpose, we developed 
a microfluidics technique, allowing kinetic measurements of adhesion, activation and aggregation of platelets 
as well as fibrin formation during thrombus build-up. By triggering specific (anti)coagulation pathways, and by 
time-dependent measurements using multiple fluorescent probes, we generated time profiles of all these pro-
cesses simultaneously. By analysing blood samples from patients with congenital defects in coagulation factors, 
we confirmed the pathophysiological relevance of alterations in thrombus formation parameters.
Results
Multiparameter assessment of platelet–fibrin thrombus formation on microspots in flowing 
whole blood. To simultaneously assess platelet activation and fibrin formation in microfluidic chambers, 
we extended an earlier microspot-based flow method, where only platelet responsiveness was  studied10. For 
this purpose, we coated coverslips with microspots (M) consisting of platelet-adhesive proteins/peptides, as 
indicated in Table 1. The microspots were coated in pairs, where only the downstream spot contained TF (to 
locally trigger extrinsic coagulation); a procedure that prevents inter-spot cross-over  effects11. Citrated blood 
was flowed through a microfluidic chamber over the microspots under conditions of two-step mixing with 
recalcification medium (Suppl. Fig. S1). Kinetic assessments were performed by capturing multicolour fluores-
cence and bright-field images per microspot every 2 min (t = 0–8 min). For each microspot, this resulted in 5 × 8 
platelet, thrombus and fibrin parameters (Table 1). Time to first fibrin formation was recorded as an additional 
parameter (P9). 
Accelerating role of tissue factor in kinetics of thrombus and fibrin formation. Based on 
the observation that co-coated TF enhances the coagulation process on  collagen11,17, we determined how 
this altered the parameters of thrombus and fibrin formation for all microspots M1–7. In the absence of TF, 
platelet deposition and aggregate formation increased in the order of M1 (BSA) < M2 (rhodocytin + VWF), 
M3 (laminin + VWF) < M4 (collagen-III), M5 (low-density collagen-I) < M6 (high-density collagen-I) < M7 
(GFOGER-GPO + VWF-BP) (Fig. 1A). Accordingly, those microspots with high GPVI activation (M6,7) gave 
the largest platelet aggregates (P1,  DiOC6) with highest phosphatidylserine exposure (P2, AF568-annexin A5) 
(Fig. 1A). In the absence of TF, only limited amounts of fibrin were formed, except for M7. However, with TF 
locally present, regardless of the type of microspot, the appearance of platelet aggregates preceded the formation 
of fibrin (Fig. 1B).
Complete data sets were then generated for microspots M1–4,6 with different amounts of TF (co-coated 
0–500 pM). Precise recording of times to first fibrin  formation18 revealed a TF dose-dependent shortening of the 
coagulation times for M2–4,6, both at high (1,000 s-1) and low (150 s-1) wall shear rate (Suppl. Fig. S2).
Evaluating the effects of high TF co-coating in more detail, we noticed a marked similarity between the shear 
rates of 1,000 s-1 or 150 s-1, which became apparent in scaled heatmaps (Fig. 2A,C) and in subtraction heatmaps 
(Fig. 2B,D). The CLEC2-dependent surface M2 (rhodocytin) showed relatively high platelet parameters (P1–2) 
and thrombus parameters (P3–5) in the absence of TF, although TF still enhanced these parameters at high 
shear rate. For M3 (laminin), TF was most effective at high shear rate, as demonstrated by the summed scaled 
effect of 84.03 versus 13.71 for high shear versus low shear, respectively (Suppl. Table S2). For M4 (collagen-III), 
acting on platelets by weak GPVI activation, TF was only moderately active (small summed scaled effect of TF; 
Suppl. Table S2). On the other hand, for M5 (low collagen-I, evoking moderate GPVI activation), TF enhanced 
all parameters including platelet deposition—likely as a limiting factor—, irrespective of the shear rate. The 
high-collagen surface M6, i.e. strongly GPVI-activating, caused maximal platelet adhesion and thrombus activa-
tion without TF present, while TF still enhanced the formation of fibrin. Microspot M7 (GFOGER-GPO), again 
strongly GPVI-activating, behaved differently in that thrombus and fibrin formation were already maximal in 
the absence of TF (1,000 s-1). Yet, at low shear rate of 150 s-1, the presence of TF was required for appreciable 
fibrin formation on this surface. Of note, the addition of either a thrombin or FXa inhibitor completely abolished 
fibrin formation, regardless of the shear rate (data not shown)19. Taken together, these data pointed to a surface-
dependent enhancing effect of TF on thrombus formation parameters, provided that coagulation activity and 
fibrin formation were not already maximal by prior platelet activation.
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The capturing of time series of microscopic images allowed more precise analyses, in order to compare the 
kinetics of the various parameters. As a proxy approach to evaluate early and late events, we compared increases 
in parameters (scaled 0–10) during the first and second 4-min intervals of flow runs (Fig. 2E,F). This analysis 
showed that—across all surfaces and regardless of the presence or absence of TF—, platelet parameters (P1–2) 
mostly accumulated in the first interval but yet continued to increase, similarly to the growth of thrombus size 
(P3), while the other thrombus parameters (P4–6) had reached completion in the first interval. In contrast, again 
across all surfaces with(out) TF, parameters of fibrin formation (P7–8) were essentially restricted to the second 
time interval. This sequence of events is schematically modelled in Suppl. Fig. S3.
To assess the relative contributions of the two platelet parameters to the thrombus-forming process, we 
developed a mathematical regression model per microspot with(out) TF, which allowed us to determine which 
thrombus and fibrin parameters relied over time on the measured values of P1–2 (Suppl. Fig. S3). Regardless 
of the type of surface, this analysis pointed to a consistently higher contribution of P1 (65–85% of maximal 
prediction) than of P2 (40–45% of maximal) for the thrombus parameters. The predictive power (7–27% of 
maximum) was lower for the fibrin parameters, due to the large time interval between platelet accumulation 
and (late) fibrin formation. On the other hand, the data did reveal a mechanism of thrombus formation primed 
by platelet adhesion and enhanced by thrombin formation, in which fibrin accumulates depending on TF and 
the platelet-activation strength of the surface.
To further substantiate this, we determined for 10 healthy blood donors how thrombus signatures correlated 
between the two high GPVI-activating microspots M6 (collagen-I) and M7 (GFOGER-GPO). Correlation analy-
sis of all scaled values over time for the non-TF microspots gave highest positive correlations (r > 0.5, p < 10–8) 
for particularly the thrombus and fibrin parameters at later time points (Suppl. Fig. S4). For the TF microspots, 
correlations between parameters were substantially higher (Suppl. Fig. S4), thus pointing to a consistent, blood 
donor-dependent thrombus signature across the collagen-related microspots.
Table 1.  Coding of microspots (M) and parameters (P) in whole blood thrombus formation, and curve 
characteristics (C) of thrombin generation. 1st Spots were located at upstream positions. Numbering of 
variables according to appearance in heatmaps. a Binding VWF from plasma. PtdS phosphatidylserine.
M 1st Spot Receptors 2nd Spot Pathway
Co-coating TF
M1 Control BSA None  + TF FVIIa
M2 Rhodocytin + VWF GPIb, CLEC2  + TF FVIIa
M3 Laminin + VWF GPIb, α6β1  + TF FVIIa
M4 Collagen-III (VWF)a GPIb, VI, α2β1  + TF FVIIa
M5 Collagen-I low (VWF)a GPIb, VI, α2β1  + TF FVIIa
M6 Collagen-I high (VWF)a GPIb, VI, α2β1  + TF FVIIa
M7 GFOGER-(GPO)n + VWF-BP GPIb, VI, α2β1  + TF FVIIa
Co-coating anticoagulant
M8 Collagen-I + TM GPIb, VI, α2β1  − TM Protein C
M9 Collagen-I + APC GPIb, VI, α2β1  − APC Protein C
P Time (min) Image type Description Unit
Platelet parameters
P1 0–8 DiOC6 Platelet adhesion %SAC
P2 0–8 AF568-annexin A5 Platelet PtdS exposure %SAC
Thrombus parameters
P3 0–8 Bright-field Thrombus coverage %SAC
P4 0–8 Bright-field Thrombus morphology score 1–5
P5 0–8 Bright-field Thrombus aggregation score 1–3
P6 0–8 Bright-field Thrombus contraction score 1–3
Fibrin parameters
P7 0–8 AF647-fibrin(ogen) Fibrin deposition %SAC
P8 0–8 Bright-field Fibrin score 1–3
P9 0–8 (10) AF647-fibrin Shorter time to fibrin 11—t min
C Curve characteristic Unit
C1 Shorter time to first thrombin min
C2 Endogenous thrombin poten-tial (ETP) nM • min
C3 Thrombin peak nM
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11910  | https://doi.org/10.1038/s41598-020-68438-9
www.nature.com/scientificreports/
tf‑dependent regulation of intrinsic coagulation pathway. The findings so far pointed to a consist-
ent accelerating role of the extrinsic TF/FVIIa pathway, mostly on parameters of thrombus and fibrin forma-
tion. As earlier flow studies suggested that the intrinsic FXII-triggered coagulation pathway is relatively slow in 
 onset13, we also examined these kinetics. Therefore, citrate-anticoagulated blood samples were pre-incubated 
with blocking agents, inactive FVIIa (iFVIIa, 1 μM) and/or CTI (40 μg/mL, added upon blood drawing), and 
flowed over microspots M1–4 and M6–7 with(out) co-coated TF at high shear rate (1,000 s-1).
In the absence of TF, blocking the extrinsic pathway with iFVIIa decreased only the thrombus parameters on 
M4,6 (Fig. 3A). As expected, iFVIIa caused a pronounced suppression of both thrombus and fibrin parameters on 
TF-containing microspots (Fig. 3B), confirming its TF-inactivating, thrombin-suppressing effect. On the other 
hand, CTI had a moderate inhibitory effect on fibrin formation in the absence of TF, but a substantially larger 
inhibitory effect with TF present, especially for the reactive (GPVI-dependent) surfaces M6–7. Strikingly, with 
TF present, the combination of iFVIIa and CTI had a stronger inhibitory effect on thrombus (P3–6) and fibrin 
(P7–9) parameters for surfaces M2–4 than iFVIIa alone (Fig. 3B). Similarly, for microspots M6–7 plus TF, the 
iFVIIa + CTI combination reduced fibrin formation more profoundly than iFVIIa or CTI did alone (medians, 
p = 0.001 for M6, p = 0.01 for M7). Accordingly, these results indicated a stimulating effect of immobilized TF 
on the intrinsic (FXII) coagulation pathway concerning overall thrombus formation and fibrin clot formation.
prediction modelling of extrinsic and intrinsic coagulation pathways. Using the raw datasets of 
all flow runs (Data File 2), we performed mathematical modelling to predict values for the separate or combined 
presence of TF, iFVIIa and/or CTI, also assuming interactions between the pathways (Suppl. Fig. S3). Using 
the constructed model, prediction for the presence of either TF, iFVIIa or CTI increased from M2 (mean 54%) 
to M7 (mean 74%), in agreement with an overall increase in effects of these interventions on the microspots 
(Suppl. Table S1). A similar increase was seen, when calculating the prediction accuracy of combined effects. 
This modelling hence indicated that the presence of TF, iFVIIa and/or CTI resulted in a consistent pattern of 
platelet–fibrin thrombus formation, especially on the active collagen and collagen-related microspots.
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Figure 1.  Simultaneous analysis of platelet deposition, thrombus phenotype and fibrin formation during whole 
blood thrombus formation under flow. Citrated whole blood from control subjects (n = 5–10) was supplemented 
with fluorescent labels to simultaneously detect platelet adhesion  (DiOC6), procoagulant, phosphatidylserine 
(PtdS)-exposing platelets (AF568-annexin A5) and fibrin formation (AF647-fibrinogen). Blood samples were 
co-perfused with  CaCl2/MgCl2 over indicated microspots, at a shear rate of 1,000 s-1. Microspot coding: M1, 
blocking buffer BSA; M2, rhodocytin + VWF; M3, laminin + VWF; M4, collagen-III; M5, collagen-I low; M6, 
collagen-I high; M7, GFOGER-GPO + VWF-BP; co-coating with 500 pM TF as indicated. (A) Representative 
bright-field and fluorescence images, taken from thrombi on microspots without TF (6 min). (B) Idem, from 
thrombi on microspots co-coated with 500 pM TF (6 min). Bars = 20 µm.
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Figure 2.  Surface-dependent enhancement by tissue factor of kinetics of platelet deposition, thrombus and 
fibrin formation. Whole blood with fluorescent labels was flowed over microspots M1–7 with or without 
co-coated TF (500 pM), as for Fig. 2. Multicolour microscopic images were captured every 2 min (t = 0, 2, 4, 
6, 8 min, →), and analysed for parameters P1–9 (for coding, see Table 1). (A,B) Blood flow at high shear rate 
(1,000 s-1). (C,D) Blood flow at low shear rate (150 s-1). (A,C) Heatmaps of univariate scaled (0–10) values per 
parameter (P1–9) across surfaces with(out) co-coated TF (500 pM). (B,D) Subtraction heatmaps indicating 
relevant TF effects per parameter, filtered for changes outside range of mean ± SD. Means of flow runs, n = 5–10 
subjects. Scaling was at 0–10 across all surfaces. (E,F) Differential increase in parameters P1–9 (1,000 s-1) over 
intervals Δt1 = (0–4) min and Δt2 = (4–8) min per microspot without (E) or with (F) TF. Colour code indicates 
parameter increase (scaled 0–10 across surfaces, 8 min). Full data are given in Data File 1.
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Role of thrombomodulin‑protein c anticoagulant pathway. Endothelial thrombomodulin (TM) 
supports anticoagulation, by converting protein C into the anticoagulant protease APC in the presence of 
 thrombin9. Once formed, APC operates in complex with protein S to cleave and inactivate FVa and FVIIIa. Since 
M6 provided an active procoagulant surface (P2), we used these collagen-I microspots to assess possible antico-
agulant effects of immobilized TM or APC in microspots. Extrinsic coagulation here was triggered by the addi-
tion of TF in recalcification medium. Microscopic imaging after 6 min indicated that co-coating of collagen-I 
with TM (M8) or APC (M9) left platelet adhesion unchanged, but markedly lowered platelet phosphatidylserine 
expression (Fig. 4A–C). In addition, the formation of fibrin was significantly impaired (p < 0.001) (Fig. 4D,E). 
Subtraction heatmaps also disclosed a major inhibition of the co-coating of TM or APC on fibrin parameters 
P7–9 (Suppl. Fig. S5). In agreement with these findings, TM reduced thrombin generation profiles in plasmas 
from control subjects (Suppl. Fig. S5). This suggested that the neighbouring TM or APC diminished thrombin 
activity, likely by on-spot inactivation of coagulation factors.
In agreement with a role of the protein C pathway under flow, the addition of C4BP, known to bind and 
decrease protein S  activity20, caused a significant decrease in time to fibrin on collagen-I microspots (M6) 
(Fig. 4F). Furthermore, the addition of soluble APC (sAPC) to the blood revealed a similar delay in fibrin forma-
tion as immobilized APC (Fig. 4G). Together, these data pointed to a regulatory role of the pathway of TM, APC 
and protein S in the later stage of flow-dependent platelet–fibrin thrombus formation.
Altered thrombus formation by congenital coagulation factor abnormalities. To assess how 
the thrombus formation was altered in blood samples from patients with defects in coagulation or anticoagu-
lation factors, we selected three sets of GPVI-activating microspots with a robust thrombus build-up, i.e. M6 
(collagen-I ± TF); M7 (GFOGER-GPO ± TF); and M8 with sensitivity for anticoagulation (collagen-I ± TM; TF 
in recalcification medium). Blood was obtained from eight representative patients with known factor abnormali-
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Figure 3.  Additive contribution of extrinsic and intrinsic coagulation pathways to kinetics of whole blood 
thrombus formation. Blood from control subjects was collected into citrate with or without CTI (40 μg/mL); 
where indicated, samples were supplemented with iFVIIa (1 μM). Whole blood perfusion (1,000 s-1) was over 
microspots M1–7 (± co-coated TF, 500 pM). Analysis of parameters P1–9 over time ( →) was carried out, as 
for Fig. 2. Four conditions (± iFVIIa ± CTI) were compared per subject (n = 4–6). Data were scaled (0–10) per 
parameter (P1–9) across surfaces. (A) Subtraction heatmap representing relevant effects of CTI, iFVIIa or 
CTI + iFVIIa (no TF). (B) Idem for microspots with TF. Effects were filtered for changes outside the range of 
means ± SD. Data File 3 provides full data.
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Figure 4.  Alterations in whole blood thrombus formation by immobilized thrombomodulin or activated protein C (APC). 
(A–E) Collagen-I microspots were co-coated or not with TM (M8) or APC (M9), and subjected to whole-blood flow at 
1,000 s-1 (TF in recalcification medium). (A) Representative bright-field and fluorescence microscopic images, as in Fig. 1, 
taken after 6 min; bars = 20 µm. (B–D) Platelet deposition (B), phosphatidylserine (C) and fibrin formation (D) after 6 min of 
flow. (E), Time to fibrin formation per microspotted surface, demonstrating delaying effects of TM and APC. Means ± SEM. 
n = 10–11, *p < 0.05. **p < 0.01, ***p < 0.001. (F,G) C4BP or soluble APC (sAPC) were added to whole blood before flow 
perfusion over collagen-I microspots co-coated or not with TF (M6). Time to fibrin formation (n = 4–7) in the presence of 
C4BP (F) or sAPC (G).
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ties, associated with either a bleeding or a prothrombotic propensity (Table 2). Of note, one patient with FXI 
deficiency used aspirin medication. Ten healthy subjects served as day controls.
For structured analysis, subtraction heatmaps were generated of scaled parameter values (Fig. 5), showing 
relevant changes in platelet (P1–2), thrombus (P3–6) and fibrin (P7–9) parameters. Subtraction heatmaps after 
6 min of flow (Suppl. Fig. S6) were in line with the integrated results. Simultaneously, plasma samples collected 
from controls and patients were used for assessment of thrombin generation curves (Suppl. Fig. S6).
In comparison to the overall control samples, blood from patients 1–2, with a severe FXII deficiency (< 1%), 
was unchanged regarding platelet activation (P1–2), but overall reduced in parameters of thrombus and fibrin 
formation (P3,7,8), when TF was present (Fig. 5). This agrees with the indications for a positive interaction of 
the intrinsic and extrinsic pathways. Typically, patient 1 demonstrated a more extensive reduction than patient 
2 in extent of thrombus and fibrin formation over time (P3–9), which may be related to the intake of aspirin. 
Ellagic acid-induced thrombin generation in plasma was more severely reduced for patient 1 than for patient 2 
(Suppl. Fig. S6).
Across all microspots, a strong FXI deficiency (19%) in patient 3 was accompanied by a consistent impairment 
in (early) thrombus and (late) fibrin parameters (P3–9). On the other hand, blood from patient 4 with limited 
reduction in FXI (33%) showed a relative increase in parameters of platelet activation (P2) and fibrin formation 
(P7–9) (Fig. 5), for all microspots. Plasmas from patients 3 and 4 showed the expected impairments in patterns 
of thrombin generation (Suppl. Fig. S6).
Patients 5–6 were included because of severe congenital deficiency in FV (< 5%), associated with mild to 
severe bleeding  symptoms21, 22. In the whole-blood flow assay, for all microspots, but most strongly for M7, fibrin 
parameters were consistently impaired (Fig. 5), which is also noticed in the 6-min heatmap (Suppl. Fig. S6). 
For both patients, the lower fibrin formation was preceded by a steady and profound reduction in thrombus 
parameters. Thrombin generation triggered by ellagic acid or TF was also greatly suppressed in the patients’ 
plasmas (Suppl. Fig. S6).
Blood was furthermore analysed for patients 7–8, with a heterozygous FV-Leiden mutation, i.e. a moderate 
prothrombotic propensity. For patient 7, we found an overall increased platelet activation (P2) and fibrin forma-
tion (P7–9). This was compatible with higher TF-triggered parameters of thrombin generation. Markedly, for 
patient 8 no such changes were seen in either test.
As an integrative approach to compare the alterations in patient samples, we combined all relevant changes in 
platelet, thrombus and fibrin parameters to obtain a net summation of the decreases and increases in comparison 
to the samples from 10 healthy control subjects (Fig. 6A). This calculation confirmed the overall decreases in 
thrombus and fibrin parameters for blood from patients 1 (FXII), 3 (FXI) and 5–6 (FV). It furthermore showed 
increased platelet parameters in blood from patients 4 (FXI) and 7 (FV-Leiden), all showing a gain-of-function in 
fibrin-thrombus formation. Consistent with this, changes in the patients’ blood samples were larger in the pres-
ence of TF (coloured bars of Fig. 6A) than in the absence of TF (white bars). This underlined that TF-containing 
microspots were more discriminative in revealing altered flow-dependent fibrin-thrombus formation than the 
non-TF microspots.
To evaluate the changes in TM-protein C pathway in the patient blood samples, the observed effects of TM as 
scaled fibrin parameters (P7–9) were integrated to obtain a mean effect parameter. In comparison to the overall 
positive TM effect in control samples (black bars in Fig. 6B), we noticed a consistent TM effect in blood from 
patients 1–3, but not for the ’reactive’ blood from patient 4. Importantly, TM effects were abolished with blood 
from patients 7–8 with protein C pathway defects, i.e. FV-Leiden mutation.
Discussion
In this study we have developed a multi-parameter microfluidics platform to determine the kinetics and interac-
tions of thrombus formation in flowing whole blood under conditions that trigger specific platelet receptors and 
(anti)coagulation pathways. Key elements of the current optimized procedure are: (1) controlled two-step mixing 
of citrated blood with recalcification medium; (2) use of combined microspots with or without co-coating of (pro-
coagulant) TF and/or (anticoagulant) TM or APC; (3) kinetic measurements of multiple processes from series of 
multicolour microscopic images; (4) standardized image analysis. As a result, 41 parameter values per microspot 
were obtained, providing simultaneous information on platelet adhesion/activation, thrombus signature, and 
Table 2.  Characteristics of patients with coagulation factor abnormalities and corresponding control subjects. 
a Confirmed mutation in SHBG (sex hormone binding globulin) region (unpublished).
Subjects Deficiency Age (y) Male/female Platelets  (109/L) Haematocrit (%) Medication Factor level Refs.
Ctrl 1–10 none 30–51 5 M, 5F 214–248 40.2–45.4 None Normal n.a
Pat 1 FXII 60 M 306 48.8 Aspirin  < 1% FXII n.a
Pat 2 FXII 44 F 198 33.3 None  < 1% FXII n.a
Pat 3 FXI 18 M 260 44.1 None 19% FXI n.a
Pat 4 FXI 31 F 292 40.2 None 33% FXI n.a
Pat 5 FV 72 F 257 34.9 None  < 5% FV 22
Pat 6 FV 75 F 132 38.8 None  < 5% FV 22
Pat 7 FV-Leiden 48 F 257 38.6 None F5 1691G → A 45
Pat 8 FV-Leiden 38 F 267 37.7 None F5 1691G → A 45
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fibrin formation at defined flow and shear rates. This multiparameter analyses revealed novel insights into: (1) 
the comparative and inter-dependency of the intrinsic and extrinsic ways of fibrin formation; (2) the identified 
local role of the protein C pathway in platelet-dependent fibrin formation; (3) the fact that similar congenital 
abnormalities in coagulation factors can result in distinct kinetics of clotting activity under flow.
This approach of systematically comparing time profiles of thrombus formation on multiple platelet adhesive 
surfaces provided new insights into the regulatory pathways of the clotting process under physiological as well as 
pathophysiological conditions. Regardless of the surface, we found an overall dose-dependent enhancing effect 
of TF on thrombus build-up and contraction, preceding the formation of a fibrin clot. This pointed to a priming 
effect of (thrombin-induced) platelet activation for the onset of clotting under flow. In addition, the enhancing 
effect of TF appeared to be independent of the shear rate (1,000 or 150 s-1), while it was less pronounced on 
Platelet Thrombus Fibrin
t t t 
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Figure 5.  Altered thrombus and fibrin formation in patients with coagulation factor abnormalities. Blood 
samples from healthy day control subjects (n = 10) and patients (Pat, n = 8) with indicated coagulation factor 
abnormalities were investigated for platelet, thrombus, and fibrin formation at a shear rate of 1,000 s-1, with 
image capturing every 2 min (see Fig. 2). Image parameters (P1–9) were obtained for microspot M6 no TF (rows 
A) or with TF (rows B); M7 no TF (rows C) or with TF (rows D); M8 with TF (rows E). Data were univariate 
scaled (0–10) across surfaces per parameter for all flow runs. Differential heatmap of scaled parameters over 
time per patient in comparison to means of control subjects. Filtering applied for changes outside the range of 
means ± SD of control subjects. A green colour indicates a relevant decrease, a red colour a relevant increase in 
comparison to controls. Full data are given in Data File 5.
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Figure 6.  Integrated changes in thrombus formation in the presence or absence of TF or TM for individual 
patients with coagulation factor abnormalities. Microspot-based formation of platelet–fibrin thrombi was 
measured in whole-blood from 10 control subjects and 8 patients with coagulation factor abnormalities, as in 
Fig. 5. Relevant changes of scaled parameters in comparison to means of control subjects (Ctrl, outside range 
of means ± SD) were integrated for all time points. Bars show results from all controls (means ± SD), from a 
representative control (Ctr1) and all individual patients (Pat1 to Pat8). (A) Cumulative relevant changes of 
scaled parameters of platelet adhesion (P1–2), thrombus signature (P3–6) and fibrin formation (P7–9) across 
five surfaces. (B) Mean relevant effects of TM on fibrin parameters for control subjects and patients, assessed for 
M8.
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highly platelet-reactive surfaces (causing strong GPVI activation). These data extend the earlier reported effect 
of coated TF in combination with collagen-I on fibrin  formation18,23.
Interventions to trigger (TF) or block the extrinsic (iFVIIa) or intrinsic (CTI) coagulation pathways pro-
vided novel information on the interactions between the two pathways in flowing whole blood. Strikingly, for 
all microspot surfaces, we found larger effects of CTI on thrombus and fibrin parameters, when TF was present. 
Indeed, modelling of the predicted contribution of either pathway also revealed positive interactions of iFVIIa 
and CTI interventions, in particular for M6,7. Our findings hence point to a new mechanism of intrinsic coagu-
lation activation under flow that is promoted by the extrinsic TF pathway.
Various mechanisms can be responsible for this coagulation crosstalk. Activated platelets are known to secrete 
polyphosphate particles, which trigger FXII  activation14. Furthermore, studies with knock-out mice revealed a 
role of FXI and FXII in collagen-dependent thrombus formation in vivo and ex vivo13,24,25. The same studies also 
demonstrated a role of TF, later stabilized by FXII in vivo, hence pointing towards a TF-priming effect of FXII 
activation. Interestingly, these findings confirm very early research papers describing a role for platelets in the 
contact phase of blood  coagulation26.
Strikingly, the present microfluidics technique also allowed detection of the natural anticoagulant protein C 
pathway, involving TM and APC. Herein, TM acts as a cofactor for the activation of protein C that together with 
protein S inactivates FVa and FVIIIa, thus abrogating the formation of thrombin and  fibrin27. Other authors have 
already established that, in a static plasma system, the addition of TM or APC suppresses thrombin generation, 
which effect is partly impaired in plasmas from carriers of the FV Leiden  mutation28–30. Our group has shown that 
in flow adhesion the phosphatidylserine-exposing platelets can act as accumulating sites for FVa and  FVIIIa19. 
Together, this points to the presence of a local and acute mechanism of TM-dependent protein C activation, 
causing inactivation of FVa and FVIIIa, which operates on microspots in flowing whole blood. The existence of 
a pathway of prothrombin activation by APC in flowing plasma was reported  before31,32.
To determine the pathophysiological implications of these findings, we examined blood samples from 8 
patients with (anti)coagulation defects. Overall, the alterations in flow-dependent clot formation were in agree-
ment with the clinical phenotypes. For instance, in case of particular coagulation factor deficiencies (FV, FXI, 
FXII) a decrease in thrombin and fibrin parameters, versus an increase in parameters in patients with procoagu-
lant alterations (FV-Leiden). Markedly, platelet parameters were only decreased in case of severe FV-deficiency, 
followed by impairments in thrombus and fibrin parameters. On the other hand, we noted heterogeneity between 
patients with the same factor abnormality, although this is in general correlated with differences in thrombin 
generation profiles. The reason for this is unclear, but it has been shown that changes in a number of coagulation 
factor levels can influence the extent of APC resistance, such as detected in specialized thrombin generation tests, 
e.g. in plasmas from FV-Leiden  patients33–35. Clearly, the present whole-blood technique has as advantage that 
it integrates the alterations in platelet and plasmatic (anti)coagulation factors. Analysis of the patient samples 
further confirmed the priming effect of platelet adhesion and activation for the clotting process.
Taken together, our findings indicate that the approach of combined phenotyping of platelet–fibrin throm-
bus formation in whole blood can serve as the basis of a novel, integrative way of determining: (1) interaction 
mechanisms of the platelet and (anti)coagulation pathways, (2) haemostatic traits due to genetic or acquired 
aberrations in coagulation factors, and (3) multi-parameter algorithms for assessment of (combined) platelet and 
coagulation defects. These microfluidic methods can further aid as an important functional add-on to genetic 
information coming from full or partial genomic sequencing protocols.
Methods
Materials. Collagen type I (Horm) was from Takeda (Hoofddorp, The Netherlands). Collagen type III 
(C4407), fibrinogen (F3879), and laminin 511/521 (L6274) were from Sigma-Aldrich (Zwijndrecht, The Neth-
erlands). VWF from human plasma was isolated to homogeneity, as  described36. Recombinant human TF was 
from Dade-Behring (Breda, The Netherlands); thrombomodulin (TM) from American Diagnostica (Pfungstadt, 
Germany); activated protein C (APC) from Innovative Research (Novi, MI, USA). Rhodocytin was purified 
from the venom of the Malayan pit viper, Calloselasma rhodostoma37 and was a generous gift of Dr. K. Clemet-
son (Bern University, Switzerland). C4BP was obtained from Athens Research (Athens, GA, USA). Chemically 
synthesized triple-helical peptides were obtained from the Dept. Biochemistry, University of Cambridge (United 
Kingdom), and used as  described10,36: H-GPC(GPO)3GFOGER(GPO)3GPC-NH2 (GFOGER-GPO); and VWF-
binding peptide H-GPC(GPP)5GPRGQOGVMGFO(GPP)5GPC-NH2 (VWF-BP). Bovine serum albumin 
(BSA) was obtained from Sigma-Aldrich; d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone (PPACK) 
from Calbiochem (San Diego, CA, USA); corn trypsin inhibitor (CTI) from Haematologic Technologies (Essex 
Junction, VT, USA), and Gly-Pro-Arg-Pro from Stago (Parsippany, JN, USA). Fragmin was obtained from Pfizer 
(Capelle a/d IJssel, The Netherlands), inactivated factor VIIa (iFVIIa) from  NovoNordisk38 (Bagsvaerd, Den-
mark). 3,3′dihexyloxa carbocyanine iodide  (DiOC6) from AnaSpec (Fremont, CA, USA); Alexa Fluor (AF)568-
labeled annexin A5 from Life Technology (Carlsbad, CA, USA); and AF647-labeled human fibrinogen from 
Molecular Probes (Eugene, OR, USA).
Blood donors and blood collection. Blood was obtained from healthy volunteers free from antiplatelet 
or anticoagulant medication for at least 4 weeks. Patients and corresponding control subjects were obtained from 
the screening program for familial plasma-based causes of bleeding or thrombophilia at the University Hospital 
of Padua (Italy)39. Patient characteristics and medication use are reported in Table 2. Studies were approved by 
the local Medical Ethics Committees (Maastricht University Medical Centre, NL31480.068.10). All subjects gave 
full informed consent according to the Declaration of Helsinki and all methods were performed in accordance 
with the relevant guidelines and regulations.
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Blood was drawn by venepuncture using a vacuum container, and collected into 9 mL tubes containing 3.2% 
trisodium citrate (Greiner, Alphen a/d Rijn, The Netherlands). Blood cell counts and other haematological 
parameters were assessed with a Sysmex XN-9000 analyser (Sysmex, Chuo-ku, Kobe, Japan). The values were 
within the normal ranges, except where indicated otherwise. Global coagulation times were only assessed, if 
aberrant thrombin or fibrin generation was suspected or  detected40. For microfluidics studies, blood samples 
were kept at room temperature and used within 4 h. Blood quality was checked during measurements. Where 
indicated, blood samples were centrifuged twice to obtain platelet-free  plasmas41. The plasmas were snap-frozen, 
and stored at − 80 °C until use.
preparation of microspot coatings. Using a precision mall, cleaned and degreased glass coverslips 
(24 × 60 mm, Thermo-Fisher, Breda, The Netherlands) were fresh daily coated with two microspots (~ 1 mm 
diameter, 5 mm centre-to-centre distance), with or without TF, TM or APC. To prevent cross-over effects, the 
most active microspot (with TF or without TM/APC) was placed  downstream11. Coating was performed with 
2.0 μL of the following solutions (Table 1): M1, BSA control (1% BSA-containing blocking buffer); M2, rhodo-
cytin (250 μg/mL) + VWF (50 μg/mL); M3, laminin (100 μg/mL) + VWF (50 μg/mL); M4, collagen-III (100 μg/
mL); M5, collagen-I low (10 μg/mL); M6, M8–9, collagen-I high (50 μg/mL); and M7, GFOGER-GPO (250 μg/
mL) + VWF-BP (100 μg/mL). Coating concentrations were optimized to achieve maximal platelet adhesion, as 
 described10. Where indicated, suspensions of TF, TM or APC (2.0 μL) were post-coated after 1 h at one of the 
spots (after washing with saline). For M1–7, maximal co-coating concentrations of TF (500 pM); for M8, TM 
(10 nM or 0.7 μg/mL); for M9, APC (10 nM or 0.6 μg/mL). Before start of the regular measurements, the activity 
of co-coated TF was checked as a consistent acceleration of fibrin formation.
Absence of cross-over effects between the two microspots was verified by altering positions and checking 
key parameters of thrombus  formation11. After coating, the coverslips were blocked with BSA-containing Hepes 
buffer pH 7.45 (136 mM NaCl, 10 mM Hepes, 2.7 mM KCl, 2 mM  MgCl2, 0.1% glucose, 1% BSA), mounted onto 
a transparent flow chamber (height 50 μm, width 3.0 mm, length 30 mm), and pre-rinsed with Hepes buffer pH 
7.45 containing 0.1%  BSA10.
Recalcification of blood and mixing in the flow chamber. During recalcification, samples of cit-
rated blood (1,000 µL) were perfused through a flow chamber using two pulse-free micro-pumps (Model 11 
Plus, 70–2,212, Harvard Apparatus, Holliston, MA, USA), and a y-shaped mixing tubing. The recalcification 
medium for co-perfusion consisted of 32 mM  MgCl2 and 63 mM  CaCl2 in Hepes buffer pH 7.45 (in another 
1 mL syringe). Mixing was at a volume ratio of 10 (blood) to 1 (recalcification medium), at flow rates to achieve 
the calculated wall shear rate in the chamber of 150 or 1,000 s-1. Additional mixing of the blood and medium 
was achieved by sudden flow profile change from round to flat at the flow-chamber entry side; complete mixing 
was confirmed by computer modelling of the fluid dynamics (Suppl. Fig. S1). Where indicated, samples were 
pre-incubated with FVIIa inhibitor (iFVIIa, 1.0 μM) and/or corn trypsin inhibitor (CTI, 40 μg/mL), which was 
added during blood taking. Typically, for experiments with microspots M8–9, TF (10 pM) was added to the 
recalcification medium. As a standard procedure, blood samples were pre-labelled with final concentrations of 
 DiOC6, (0.5 μg/mL, staining all platelets), AF647-fibrinogen (8.5 μg/mL), and AF568-annexin A5 (4.0 μg/mL, 
staining phosphatidylserine-exposing platelets).
Full mixing of blood with recalcification medium was achieved by a simple, but effective two-step mixing 
procedure. The first step was provided by an in house fabricated y-shaped Versitec silicone tubing (1.0 mm ID, 
3.0 mm OD, Saint-Gobain Plastics, France); this was constructed by perforating the tubing laterally (at 1 cm 
from outlet, angle 30°) with a 18G needle placed inside-out, after which a second tubing was connected to the 
needle tip. Leakage-free sealing was obtained using liquid polymerizing silicone; the needle was removed after 
polymerization. This resulted in a small pore (~ 0.5 mm) in the main tubing wall, through which the recalci-
fication medium could be pressure-injected. The second mixing step was provided at the flow chamber inlet, 
by transition from a tubular (1 mm Ø) to flat (50 µm height, 3 mm width) cross-section, resulting in sudden 
redistribution of the flow velocity profile. This set up ensured consistent mixing, a low shear rate at the inlet, and 
a higher-shear laminar flow pattern inside the parallel-plate chamber (Suppl. Fig. S1).
Real‑time detection of platelet–fibrin thrombus formation on microspots. Bright-field and fluo-
rescence microscopic images were acquired from each of the microspots during blood flow at t = 0, 2, 4, 6, 8 
(to 10) min. Image recording was performed with an inverted EVOS fluorescence microscope (Life Technol-
ogy, Ledeberg, Belgium), equipped with bright-field illumination, three LED diode cubes (GFP 470 nm, RFP 
531  nm and Cy5 626  nm), and an Olympus 60 × oil-immersion objective with high z-axis resolution (UPL-
SAPO60, numerical aperture 1.35). Monochromatic images were collected at 8 bit (1,360 × 1,024 pixels, resolu-
tion 0.108 μm per pixel). In specific cases, images were collected using a multicolour confocal microscope (simi-
lar excitation wavelengths), as  described11. Duplicate flow runs were performed per blood sample, or triplicate 
runs in case of marked variation.
Standardized image analysis and delineation of thrombus outcome parameters. Images were 
analysed using semi-automated scripts, written in the open-access program  Fiji42. Specific scripts were designed 
for images of bright-field and each fluorescent label. In the scripts, optimized fast Fourier transformation was 
applied to reduce background noise and filtering down image-wide structures. Subsequently, morphological 
vertical and horizontal dilate and erode steps were applied to remove noise pixels and to enhance relevant struc-
tures. Overlay images were generated to verify the binary mask images, and scripts looped back to reset thresh-
olds if the analysis was incorrect. Thresholding was checked against t = 0 images.
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Together, the binary bright-field and fluorescence images gave nine parameters (P1–9) per time point (see 
Table 1). The  DiOC6 images reported on platelet deposition (P1); while the AF568-annexin A5 images indicated 
phosphatidylserine-exposing platelets (P2). Enhanced bright-field images were also analysed for platelet adhe-
sion (P3). Bright-field images were analysed for thrombus morphology (P4): 0, no or few adhered platelets; 1, 
multiple single adhered platelets; 2, extensive coverage of single adhered platelets; 3, small platelet aggregates; 
4, medium-size aggregates and thrombi; 5, large aggregates and  thrombi10. Bright-field images were also scored 
(scale 0–3) for thrombus aggregation (P5) and thrombus contraction (P6). Regarding fibrin, AF647-fibrin(ogen) 
images provided information on fibrin deposition (P7), with thresholds set above values for fibrinogen  binding11; 
bright-field images further gave a fibrin score on a scale of 0–3 (P8). Furthermore, shortening of the time to first 
fibrin formation (default t = 11 min) were recorded (P9). Fibrin formation was precisely quantified in real time 
from the appearance of growing fibres protruding from the platelet  thrombi18. All scoring was in comparison to 
a set of pre-selected, representative images. Analysts were blinded to the experimental conditions. As described 
before, variation of key thrombus forming parameters for collagen-I was 15% (median)43. In addition, intra-
individual variation of time to fibrin was 7–12%.
calibrated automated thrombin generation. Thrombin generation was measured in platelet-free 
plasma samples (total volume 120 μL) using a 96 wells plate assay, basically as  described41. Briefly, 80 μL plasma 
samples were incubated with 4 μM phospholipid vesicles (PS/PE/PC, 20/20/60, w/w/w) at 37 °C for 10 min, and 
subsequently mixed with 20 μL prewarmed trigger reagent containing either TF (1 pM, f.c.), ellagic acid (10 μg/
mL, f.c.) or TM (0.325 nM, f.c.) and with 20 μL fluorogenic thrombin substrate (Z-Gly-Gly-Arg AMC) contain-
ing  CaCl2. After mixing, thrombin generation was measured per well using Thrombinoscope software (Thrombi-
noscope, Maastricht, The Netherlands). Standard curve parameters were obtained, as indicated in Table 1.
predictions of contribution of extrinsic and intrinsic pathways of coagulation. Models were 
made in Matlab for the predicted contribution of parameters to thrombus formation at all time points, using 
the conditions with or without TF, CTI or iFVIIa, thus making in total 8 combinations or classes. Raw data 
were loaded into Matlab, and (few) missing values were estimated using the function Knnimpute. Per micros-
pot, 8-class predictions were run, in each case using 17 different machine learning programs (Weka classifiers: 
SimpleCart, BayesNet, NaiveBayer, Logistic, RBFNetwork, SMO, AggregationPerception, IB1, ConjunctiveRule, 
JRip, NNge, PART, BFTree, FT, J48, RandomForest, REPTree). Accuracies were calculated by leave-one-out cross 
validation. The predictions tested the hypothesis if the presence/absence of TF, iFVIIa or CTI significantly altered 
parameters of fibrin-thrombus formation per microspot. In other words, if the measured parameters allow to 
predict which of these factors is present. In addition, per class variable (TF, iFVIIa, CTI), t-tests (2-sided) were 
run to compare the performances of the 17 algorithms on every pair of surfaces, after correction for false dis-
covery rate. These models were also checked by cross-validating, leave-one-out predictions. Linear regression 
models to predict P3–9 outcomes over time from P1–2 were also constructed in Matlab.
Bioinformatics and statistics. Relationships between parameters were calculated by multiple regression 
analysis using the statistical package for social sciences (SPSS version 22). For comparative data analysis in heat-
maps, mean values per parameter across surfaces were linearly scaled to a range from 0–10. One-way unsuper-
vised hierarchical clustering was performed using the R version 3.2.5 (www.r-proje ct.org). Euclidean distances 
were calculated, and clustering was by complete linkages. In order to visualize effects of TF co-coating or of 
interventions, scaled parameters were linearly subtracted to obtain subtraction heatmaps.
Numerical data of interventions are presented as means with SEM. Data from individual patients were com-
pared, as described  before44, to normal ranges established for a cohort of control subjects (set as means ± SD). 
Blood samples from patients and controls were analysed in parallel over the same period. Statistical comparison 
was by probability analysis (Mann–Whitey U-test for numerical or continuous variables). Values of p < 0.05 were 
considered significant.
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